Back to results
US 2019/0240358 A1Published application
3e8.scfv.cys-ir800 conjugate targeting tag-72 in an orthotopic colorectal cancer model
AssigneeOhio State Innovation Foundation
InventorsMichael F. Tweedle, Li Gong
Life of this patent
Estimating the term…
Abstract
Disclosed are compositions are anti-TAG-72 imaging agents and methods of their use.
Claims18
An anti-TAG-72 imaging agent comprising the formula Y-R, wherein Y comprises an anti-TAG-72 binding moiety and R comprises a first detectable label;
- wherein the first detectable label “R” comprises any dicyanine dye that emits fluorescent light that is detectable on a clinical optical NIRF imager at primarily above 800 nm.
An anti-TAG-72 imaging agent comprising the formula Y-R, wherein Y comprises an anti-TAG-72 binding moiety and “R” comprises a first detectable label;
- wherein the anti-TAG72 binding moiety “Y” comprises 3E8.scFv.Cys and wherein the first detectable label “R” comprises IRdye800.
A method of making ®-anti-TAG-72 imaging agent comprising the formula Y-R, wherein Y comprises an anti-TAG-72 binding moiety and R comprises a first detectable label;
- wherein ® is a radioactive labeling atom that is useful for SPECT/CT or PET/CT, a radioactive labeling atom that is useful for RADS surgical guidance, or a radiolabeling atom useful for both SPECT/CT or PET/CT and RADS said method comprising
- a. providing an anti-TAG-72 imaging agent comprising a tyrosine residue;
- and
- b. reacting the biomolecule with a chloramine and an iodine source under conditions effective to form an iodinated biomolecule, wherein the iodinated biomolecule comprises an iodinated tyrosine residue.
1 more element
Dependencies are inferred from the claim text.